FIELD: medicine; hematology.
SUBSTANCE: invention can be used to determine the prognosis of relapse in patients with acute myeloid leukemia (AML) based on the results of the assessment of minimal residual disease (MRD) in the post-induction phase of treatment after the 1st checkpoint — in the period from the 35th to the 42nd day after the 1st course of induction chemotherapy and the 2nd checkpoint — in the period from the 70th to the 84th day after the 2nd course of induction chemotherapy. Residual tumor cells are detected by multicolor flow cytometry in patients with acute myeloid leukemia at two control points. At the first stage, all CD34-positive cells are isolated and sequentially analyzed for the expression of all antigens, isolating all CD34-positive cells normally present in healthy donors. At the second stage, all CD117-positive cells are isolated and sequentially analyzed for the expression of all antigens, isolating all CD117-positive cells normally present in healthy donors. At the third stage, all CD117-CD34-cells are isolated and sequentially analyzed for the expression of all antigens, isolating all CD117-CD34 cells normally present in healthy donors. When diagnosing the presence of MRD after the 1st course and/or the 2nd course, a relapse is predicted in patients with AML. Bone marrow sample preparation includes lysis of erythrocytes and staining of leukocytes with a panel of monoclonal antibodies.
EFFECT: method provides the possibility of increasing the efficiency of assessing MRD status in patients with AML, selecting a threshold value for establishing MRD-positive status, identifying the risk of relapse in patients with AML by determining the patient's MRD status by multicolor flow cytometry using gating and staining of leukocytes with a panel of monoclonal antibodies.
4 cl, 6 dwg, 6 tbl, 6 ex
